Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | March 13, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date March 13, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,520 |
Last balance in matching sequence
After 2026-03-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-13 · Exercise / conversion · Acquired 30,000 · Balance 135,520 F1: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person. Row 2 · 2026-03-17 · Gift · Disposed 30,000 · Balance 105,520 F2: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. F1: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 30,000 |
Reported balance
After 2026-03-17 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-03-17 · Gift · Acquired 30,000 · Balance 30,000 F2: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. F3: Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 50,990 |
Reported balance
Holding disclosure · report date 2026-03-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 50,990 F4: Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2027-06-06 | Direct | 23,837 |
Reported balance
After 2026-03-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-13 · Exercise / conversion · Disposed 30,000 · Balance 23,837 F5: The Reporting Person is exercising this option due, in part, to its near-term expiration date. F6: These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.
F2: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust.
F4: Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.
F5: The Reporting Person is exercising this option due, in part, to its near-term expiration date.
F6: These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 18, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-009900 · form4.xml · nonDerivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 30,000 F2 · kind: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. F3 · ownership.nature: Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-009900 · form4.xml · nonDerivative · entry 2 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,520 F2 · kind: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. F1 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001140361-26-009900 · form4.xml · derivative · entry 5 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,837 Underlying: Common Stock · 30,000 shares Expires 2027-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The Reporting Person is exercising this option due, in part, to its near-term expiration date. F6 · derivative.exercise_date: These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 30,000 | $3.66 | $109,800.00 |
DisclosureSEC source: 0001140361-26-009900 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 17,730 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-26-004886 · form4.xml · derivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 17,730 shares Expires 2036-02-09 F4 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-004886 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,520 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 89,385 shares of common stock owned by the Reporting Person. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 20,000 | $20.96 | $419,200.00 |
DisclosureSEC source: 0001140361-25-022240 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,830 F1 · balance_after: Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 83,941 shares of common stock owned by the Reporting Person. Read SEC document |
| May 22, 2025 Filed May 24, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 1,221 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001140361-25-020376 · form4.xml · derivative · entry 7 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,221 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The Reporting Person is exercising this option due, in part, to its near-term expiration date. F6 · derivative.exercise_date: These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. Read SEC document |
| May 22, 2025 Filed May 24, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 1,221 | $20.12 | $24,566.52 |
DisclosureSEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 4 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,830 F2 · balance_after: Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 103,941 shares of common stock owned by the Reporting Person. The number of common shares reported includes a de minimis reduction by 10 shares from the amount previously reported due to a broker adjustment. Read SEC document |
| May 22, 2025 Filed May 24, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 1,221 | $5.96 | $7,277.16 |
DisclosureSEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2025 Filed May 24, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 7,779 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001140361-25-020376 · form4.xml · derivative · entry 6 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,221 Underlying: Common Stock · 7,779 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The Reporting Person is exercising this option due, in part, to its near-term expiration date. F6 · derivative.exercise_date: These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. Read SEC document |
| May 21, 2025 Filed May 24, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 7,779 | $20.32 | $158,069.28 |
DisclosureSEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 2 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,830 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 21, 2025 Filed May 24, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 7,779 | $5.96 | $46,362.84 |
DisclosureSEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 16,279 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005542 · form4.xml · derivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,279 Underlying: Common Stock · 16,279 shares Expires 2035-02-19 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005542 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,830 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 restricted stock units granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (iii) 141,921 shares of common stock owned by the Reporting Person. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 9,000 | $10.80 Strike: $10.80 | $97,200.00 |
DisclosureSEC source: 0001140361-24-040872 · form4.xml · derivative · entry 4 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2025-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date. F4 · derivative.exercise_date: These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 9,000 | $18.47 | $166,188.60 |
DisclosureSEC source: 0001140361-24-040872 · form4.xml · nonDerivative · entry 2 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,941 F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $18.465 to $18.47. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (ii) 141,921 shares of common stock owned by the Reporting Person. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 9,000 | $10.80 | $97,200.00 |
DisclosureSEC source: 0001140361-24-040872 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 37,541 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001140361-24-010240 · form4.xml · derivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,541 Underlying: Common Stock · 37,541 shares Expires 2034-02-26 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 24,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-010240 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,941 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023 which will vest in full on March 6, 2024; and (iii) 104,086 shares of common stock owned by the reporting person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 51,630 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-23-010770 · form4.xml · derivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,630 Underlying: Common Stock · 51,630 shares Expires 2033-03-06 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 25,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010770 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,901 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 90,793 shares of common stock owned by the reporting person. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:59 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 53,172 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001140361-22-008675 · form4.xml · derivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,172 Underlying: Common Stock · 53,172 shares Expires 2032-03-07 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:59 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 26,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-008675 · form4.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,086 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 77,500 shares of common stock owned by the reporting person. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:04 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001193805-21-000297 · e620332_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:10 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001193805-20-000289 · e619423_4-guiheen.xml · derivative · entry 3 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-28 F4 · derivative.exercise_date: The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:10 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000289 · e619423_4-guiheen.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 70,000 shares of common stock owned by the reporting person. Read SEC document |
| February 28, 2020 Filed May 1, 2020 21:10 UTC Amendment | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000550 · e619596_4a-guiheen.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 F1 · shares: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 70,000 shares of common stock owned by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 15:18 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 20,000 | $3.50 | $70,000.00 |
DisclosureSEC source: 0001193805-20-000135 · e619337_4-guiheen.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| May 17, 2019 Filed May 21, 2019 11:13 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0001193805-19-000523 · e618482_4-guiheen.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001193805-19-000297 · e618307_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-03-13 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001193805-18-000902 · e618127_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:09 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 20,000 | $4.78 | $95,600.00 |
DisclosureSEC source: 0001193805-18-000819 · e618085_4-guiheen.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:04 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001060 · e616267_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000282 · e615795_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.